EUVIMEDEUVIMED entdecken
Fallbericht

Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation

G Abebe Campino iD, S Shrot, S Constantini, J Roth, A Toren, M Lurye, M Yalon-Oren

Child's Nervous System · 2025

DOI: 10.1007/s00381-025-07084-w ↗

Kurz gefasst

Fallbericht in der Zeitschrift Child's Nervous System, 2025. Verfasst von G Abebe Campino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat Gan, Israel. gadi.…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Imidazoles, Glioma, Mutation. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Children with unresectable cervicomedullary tumors (CMTs) demonstrate poor progression-free survival when treated with conventional chemotherapy and radiotherapy. The BRAFV600E mutation, commonly identified in low-grade gliomas, represents a therapeutic target for mutation-specific kinase inhibitors. This study aims to emphasize the potential role of BRAF inhibitors as upfront targeted therapy in selected tumors where surgical resection is not feasible. METHODS: A retrospective analysis was conducted on four pediatric patients with unresectable cervicomedullary low-grade gliomas harboring the BRAFV600E mutation. All patients were treated with the BRAF inhibitor dabrafenib, either as first-line or second-line therapy. RESULTS: Dabrafenib was administered as first-line therapy in two patients and as second-line therapy in two others. All patients experienced rapid tumor regression with significant and durable clinical and radiologic responses. Three patients tolerated long-term therapy (up to 9 years) without significant toxicity. One patient discontinued treatment after 1 year due to a serious adverse event, which resolved upon withdrawal of therapy. CONCLUSION: Dabrafenib demonstrated clinical and radiographic efficacy and was generally well tolerated in pediatric patients with unresectable BRAFV600E-mutant CMTs. These findings suggest that upfront BRAF inhibition may serve as a viable therapeutic alternative to conventional chemotherapy, radiotherapy, or attempted resection in selected cases. Further prospective studies are warranted to define the optimal timing, duration, and long-term safety of targeted therapy in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafImidazolesGliomaMutationOximesAntineoplastic AgentsSpinal Cord NeoplasmsBrain Stem NeoplasmsHumansMaleFemaleChildRetrospective StudiesChild, PreschoolAdolescentTreatment Outcome

Stichwörter der Autor:innen

BRAFV600ECentral nervous systemCervicomedullary tumorDabrafenibPediatric low-grade glioma

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humandabrafenibImidazolesOximesAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat Gan, Israel. gadi.abebe-campino@sheba.health.gov.il.
  • The Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. gadi.abebe-campino@sheba.health.gov.il.
  • Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
  • The Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Pediatric Neurosurgery, The Pediatric Brain Center, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
  • Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 5262000, Ramat Gan, Israel.

ORCID-Profile: G Abebe Campino

Zitieren

APA

Campino, G. A., Shrot, S., Constantini, S., Roth, J., Toren, A., Lurye, M., & Yalon-Oren, M. (2025). Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation. Child's Nervous System. https://doi.org/10.1007/s00381-025-07084-w

Vancouver

Campino GA, Shrot S, Constantini S, Roth J, Toren A, Lurye M, et al. Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation. Child's Nervous System. 2025. doi:10.1007/s00381-025-07084-w

BibTeX
@article{Campino2025,
  author = {Campino, G Abebe and Shrot, S and Constantini, S and Roth, J and Toren, A and Lurye, M and Yalon-Oren, M},
  title = {Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation},
  journal = {Child's Nervous System},
  year = {2025},
  doi = {10.1007/s00381-025-07084-w}
}
Kostenlos starten →